Company Profile

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg. Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2).

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma India is currently trading at Rs. 3954.00, up by 58.90 points or 1.51% from its previous closing of Rs. 3895.10 on the BSE.

The scrip opened at Rs. 3901.00 and has touched a high and low of Rs. 3957.50 and Rs. 3901.00 respectively.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4970.00 on 08-Sep-2020 and a 52 week low of Rs. 1888.00 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 3957.50 and Rs. 3598.75 respectively. The current market cap of the company is Rs. 9737.75 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 3.82% and 21.18% respectively.

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg. Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2).

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Hindustan Aeronautics (HAL) has signed a memorandum of understanding (MoU) with Safran Aircraft Engines, France at Aero India 2021 to explore opportunities for strategic business cooperation that leverage the complementary talents and capabilities of the both parties and support development of a robust ecosystem for aero-engines in India, consistent with the goals of the Government of India's Make in India initiative.

Bharat Dynamics (BDL) has launched two new products during Aero India- 2021 - the ‘Dishani’ and ‘Garudastra’. Garudastra is an advanced anti submarine self guided state of the art homing torpedo being designed and developed by NSTL, DRDO with BDL as the development partner. Dishani, an expendable air-deployed ASW sonobuoy system being designed and developed by NPOL, DRDO. BDL is the development partner for Dishani.

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg. Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m2). The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

Tata Motors has opened bookings of the all-new Safari. Customers can book this new premium SUV at a refundable amount of Rs 30,000 on https://cars.tatamotors.com/suv/safari or visit the nearest Tata Motors Authorized Dealership and be on the priority delivery list. The vehicles are now on display and available for test drives across the company’s dealer network. Furthermore, price announcement and deliveries of the all-new Safari will begin on February 22, 2021.

Gulf Oil Lubricants’ board has approved to enter into an agreement with Gulf Oil International (GOI) to participate and co-invest in GOI's recent investment along with the Clean Growth Fund (CGF- a UK venture capital fund) in Indra, the UK Based Electric vehicle (EV) and smart energy technology company developing innovative charging and energy storage solutions for home and commercial use. With this investment, Gulf India will get access to an established technology in EV charging space to adopt the same for Indian conditions and leverage its wide distribution and brand strengths to extend Gulf Branded residential and commercial charging points as per the evolving needs of Indian consumers.

Adani Enterprises’ Wholly Owned Subsidiary-- Adani Airport Holdings (AAHL) has acquired 23.5% equity stake i.e. 28,20,00,000 Equity Shares of Rs 10 of Mumbai International Airport (MIAL) from ACSA Global (ACSA) and Bid Services Division (Mauritius) (Bidvest). MIAL is engaged in the business of development, construction and operation of Chhatrapati Shivaji Maharaj International Airport.

In keeping with its vision in achieving Sustainability, Ambuja Cements has notched yet another first with the commencement of ‘Sea trials on Bio-diesel Blends’ by one of its fleet of captive ships, ‘Ambuja Mukund’ that was conducted at sea. Ambuja has received approvals to conduct this sea trial from the Directorate General of Shipping (DGS) and the Indian Register of Shipping (IRS), thus marking a new chapter in Indian coastal shipping.

AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra). Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients. The receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt of related statutory approvals and licenses.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.